https://www.zacks.com/stock/news/2212081/compared-to-estimates-m-t-bank-corporation-mtb-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2212081
Jan 18, 2024 - While the top- and bottom-line numbers for M&T Bank Corporation (MTB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:8653296328247734161
0
https://www.zacks.com/stock/news/2209805/macy-s-m-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2209805
Jan 12, 2024 - Macy's (M) concluded the recent trading session at $18.54, signifying a -0.43% move from its prior day's close.
zc:-4840047822947871851
0
https://www.zacks.com/stock/news/2209609/exploring-analyst-estimates-for-m-t-bank-corporation-mtb-q4-earnings-beyond-revenue-and-eps?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2209609
Jan 12, 2024 - Beyond analysts' top -and-bottom-line estimates for M&T Bank Corporation (MTB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
zc:-546257670135066454
0
https://www.zacks.com/stock/news/2208935/m-t-bank-corporation-mtb-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2208935
Jan 11, 2024 - M&T Bank Corporation (MTB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:8888708998428966574
0
https://www.zacks.com/stock/news/2208293/what-s-in-store-for-m-t-bank-mtb-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2208293
Jan 10, 2024 - Increasing funding costs are likely to have hurt M&T Bank's (MTB) Q4 NII growth. Also, declining non-interest income is likely to have affected the company's top-line growth.
zc:3627358879439705571
0
https://seekingalpha.com/news/4053547-barrons-cites-cancer-weight-loss-plays-biotech-ma?source=feed_sector_healthcare
Jan 09, 2024 - On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.
0
sa:-5028790045707168747
0
https://www.zacks.com/stock/news/2207137/why-m-t-bank-corporation-mtb-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2207137
Jan 08, 2024 - M&T Bank Corporation (MTB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:-7971180440256592299
0
https://www.zacks.com/stock/news/2205804/goldman-gs-tops-in-m-a-advisory-despite-dealmaking-lull?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2205804
Jan 04, 2024 - Goldman (GS) advises on 235 announced M&As in 2023, with an aggregate value of more than $671 billion. With this, it has a 31% market share of the global merger advisory.
zc:-4226259513534166642
0
https://seekingalpha.com/news/4051438-whats-in-store-for-biotech-mergers-and-ipos-in-2024?source=feed_sector_healthcare
Jan 01, 2024 - Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
0
sa:-4453521307831458435
0
https://seekingalpha.com/news/4051040-needham-says-cytokinetics-appeal-as-ma-target-enhanced-by-hcm-data?source=feed_sector_healthcare
Dec 28, 2023 - Cytokinetics' (CYTK) attractiveness as a takeover target has been enhanced by positive data for its hypertrophic cardiomyopathy drug aficamten, according to Needham.
0
sa:-6445376147327595208
0